// App-Quantinova.ai

BRMP-03 : Pituitary carcinoma: a case of dramatic response to immunotherapy (ipilimumab + nivolumab) after failure with temozolomide

Researchers

Presenter

  • Sanjit Shah

Principal Investigators

  • Saima Manzoor

  • Yehudit Rothman

  • Matthew Hagen

  • Luke Prater

  • Karl Golnik

  • Abdelkader Mahammedi

  • Andrew Lin

  • Ruchi Bhabhra

  • Jonathan Forbes

  • Soma Sengupta

Medical Centers

  • University of Cincinnati Medical Center, Cincinnati, OH, USA

  • Memorial Sloan Kettering Cancer Center, New York, NY, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pituitary adenomas

  • Solid malignancies

Biomarkers

  • p53

  • O-6-methylguanine DNA methyltransferase

  • MutL Homolog 1

  • Mismatch repair endonuclease PMS2

  • Proliferation marker protein Ki-67

  • Tumor protein p53

Drug/Treatment

  • Temozolomide

  • Ipilimumab

  • Nivolumab

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved